Quick Answer
Cue Biopharma, Inc. reported Operating Income Loss of -$26.55 million for the year ending 2025.
- Cue Biopharma, Inc. showed an increase of +36.0% in Operating Income Loss from 2024 to 2025.
- This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$3.35 million | Q2 2017: -$4.41 million | Q3 2017: -$5.03 million | Q1 2018: -$7.52 million | Q2 2018: -$7.47 million | Q3 2018: -$12.76 million | Q1 2019: -$11.43 million | Q2 2019: -$9.23 million | Q3 2019: -$7.09 million | Q1 2020: -$13.00 million | Q2 2020: -$10.94 million | Q3 2020: -$10.13 million | Q1 2021: -$12.52 million | Q2 2021: -$10.30 million | Q3 2021: -$13.02 million | Q1 2022: -$14.24 million | Q2 2022: -$13.09 million | Q3 2022: -$11.03 million | Q1 2023: -$13.38 million | Q2 2023: -$13.52 million | Q3 2023: -$11.42 million | Q1 2024: -$12.67 million | Q2 2024: -$10.38 million | Q3 2024: -$8.82 million | Q1 2025: -$12.30 million | Q2 2025: -$8.64 million | Q3 2025: -$7.60 million.
- Over the full 9 years of available data (2017 to 2025), Cue Biopharma, Inc.'s Operating Income Loss has declined by 14.3%.
- Historical annual values: Fiscal year 2025: -$26.55 million | Fiscal year 2024: -$41.50 million | Fiscal year 2023: -$52.15 million | Fiscal year 2022: -$53.23 million | Fiscal year 2021: -$43.71 million | Fiscal year 2020: -$45.04 million | Fiscal year 2019: -$36.77 million | Fiscal year 2018: -$38.70 million | Fiscal year 2017: -$23.23 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: